XML 66 R47.htm IDEA: XBRL DOCUMENT
v3.25.1

Segment Information (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Segment Reporting [Abstract] |
Reconciliation of revenue from segments to consolidated | The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:
|  | For the Three Months Ended March 31, |  |
(In millions) |  | 2025 |  | 2024 |  |  |  |
Total revenue |  | $ | 2,431.0 |  |  | $ | 2,290.5 |  |  |  |  |
Less cost and expense: |  |  |  |  |  |  |  |
Cost of sales, excluding amortization and impairment of acquired intangible assets: |  |  |  |  |  |  |  |
Product cost of sales |  | 462.2 |  |  | 377.7 |  |  |  |  |
Royalty cost of sales |  | 167.1 |  |  | 164.5 |  |  |  |  |
Research and development: |  |  |  |  |  |  |  |
Research and discovery |  | 44.3 |  |  | 47.6 |  |  |  |  |
Early stage programs |  | 72.4 |  |  | 84.1 |  |  |  |  |
Late stage programs |  | 49.4 |  |  | 32.6 |  |  |  |  |
Marketed products |  | 89.5 |  |  | 118.1 |  |  |  |  |
Other research and development costs(1) |  | 178.5 |  |  | 163.0 |  |  |  |  |
Acquired in-process research and development, upfront and milestone expense |  | 200.7 |  |  | 7.5 |  |  |  |  |
Selling, general and administrative |  | 572.5 |  |  | 581.5 |  |  |  |  |
Other segment expense(2) |  | 353.9 |  |  | 320.5 |  |  |  |  |
Net Income attributable to Biogen Inc. |  | $ | 240.5 |  |  | $ | 393.4 |  |  |  |  |
(1) Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage. (2) Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; other (income) expense, net; and income tax (benefit) expense

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration